Article Type : Case Report
Authors : Ogawa H, Bando H, Abe T, Nagahiro S, Nakanishi M and Watanabe O
Keywords : Oral semaglutide (Rybelsus); Type 2 diabetes (T2D); Gastro Esophageal Reflux Disease (GERD); Gastrointestinal adverse effects (GIAEs); Sodium N-[8-(2-hydroxybenzoyl) amino] caprylate (SNAC)
Background: Oral semaglutide (Rybelsus) has been recently in focus for type 2 diabetes (T2D).
Case presentation: Case is 61-year-old female with T2D, obesity, fatty liver and Gastro Esophageal Reflux Disease (GERD). Her HbA1c was 13.2% in Dec 2021, and she started to have metformin, empagliflozin and Rybelsus from 3mg to 7mg/day. General situation was improved as -4.2% of HbA1c and -8kg in weight for 4 months.
Discussion and Conclusion: This case has GERD, and then the doses of Rybelsus kept 7mg/day. She did not feel any gastrointestinal adverse effects (GIAEs). This impressive case will become reference for diabetic practice.
Medical and social
problems of obesity and diabetes have been more in focus in developed and
developing countries [1]. These situation may cause unsatisfactory activity of
daily livings (ADL) and quality of life (QOL) [2]. Especially, patients with
type 2 diabetes (T2D) have been more found who are more than 60s and 70s [3].
T2D includes various diabetic complications such as microangiopathy,
macroangiopathy, sarcopenia and other impaired functions [4]. As to adequate
diagnosis and treatment of T2D, latest guideline for standard diabetic care was
announced by American Diabetes Association (ADA) in January 2022 [5].
Recommended level of adequate glucose control has been presented for a various
situation of diabetic patients [6].
As regard to diet
therapy, calorie restriction (CR) was formerly standard method. After that, low
carbohydrate diet (LCD) method was introduced to medical and health care region
[7]. Consequently, actual LCD continuation have been understood and prevalent
across the world [8]. Authors et al. started and developed LCD socially through
the activity of Japan LCD promotion association (JLCDPA) [9]. We proposed
useful LCD method including super-, standard- and petite-LCD [10].
Concerning pharmacological therapy, ADA proposed
the recent standard treatment in the guideline [11]. They include several
agents such as glucagon-like-peptide 1 receptor agonist (GLP1-RA) [12,13] and
sodium–glucose cotransporter 2 inhibitor (SGLT2i) [11,14]. Among them, oral
semaglutide (Rybelsus) has attracted attention, that was introduced to medical
practice [15]. The important point would be the novel route that not only
injection but also oral route become possible [16]. Authors and collaborators
in diabetic medical team have so far continued several reports about glucose
variability and oral hypoglycemic agents (OHAs) [17,18]. Some cases have
applied oral semaglutide, who showed rather satisfactory clinical efficacy
[19,20]. In this article, we present an impressive case treated with oral
semaglutide.
History & Physical
The patient is a
61-year-old female patient with T2D. She was diagnosed as T2D about 12 years
ago, and has been treated by some OHAs for 4 years. Her OHAs included metformin
1000mg and Vildagliptin 100mg/day from 2018. Her HbA1c was stable, but
gradually increased to 8.8% in July 2019. She was started to be given
Empagliflozin 25mg/day. After that, her HbA1c has decreased 7.0% in March 2021.
However, her family had various problems including her father’s death and
others during summer to autumn 2021. Such situation brought her not to visit
diabetic clinic for several months (Figure 1).
Concerning her physical
examination, her consciousness, speech and vital signs are normal. Her stature
has been 164 cm and her body weight 83kg in Jan 2021 with body mass index (BMI)
31.2 kg/m2. This value of BMI means 1 degree of obesity from
international guideline. She showed unremarkable findings of lung and heart.
Her abdomen is distended, soft with normal range of bowel sound. No significant
neurological abnormality was found.
Several exams
The biochemical and other
results of Jan 2021 were summarized as follows: GOT 48 U/L,GPT 52 U/L, GGT 61
U/L, AlP 231 (100-340), LDH 163 U/L (120-240), LDL-C 115 mg/dL, TG 211 mg/dL,
HDL-C 42 mg/dL, BUN 11 mg/dL, Cr 0.76 mg/dL, eGFR 66 mL/min/1.73m2,
UA 5.2 mg/dL, Na 141 mEq/L, K 4.5 mEq/L, Cl 100 mEq/L, RBC 4.57 x 106
/?L, Hb 13.9 g/dL, MCV 83.8 fL, MCH 30.4 pg, MCHC 36.2 g/dL, WBC 7000 /?L, Plt
27.5 x 104 /?L, serum Fe 90 ?g/dL, TIBC 364 ?g/dL, UIBC 274 ?g/dL,
ferritin 74 ng/mL. For several tests for DM, post-prandial blood glucose 214
mg/dL, HbA1c 7.5 %, urinalysis findings were presented as protein (-), glucose
(++), urobilinogen (+/-), ketone body (+). Chest X-P was normal for heart and
lung, and Electrocardiogram (ECG) revealed within normal limits. Occult blood
in stool was negative, and other remarkable findings were not detected.
Clinical progress
After several month
absence, she visited our clinic again in Dec 2021. Her HbA1c and 30-min
post-prandial glucose were 13.2% and 506 mg/dL, and body weight was 85 kg. Our
medial team has consulted with the patient concerning the detail situation, and
come to judge probably successive cooperative and stable treatment progress.
Consequently, she was started to be given Rybelsus 3mg as oral semaglutide from
Dec 2021.
She could take Rybelsus 3mg satisfactory for 4 weeks. In Jan 2022, Her HbA1c and 30-min postprandial glucose after breakfast were 12.3% and 228mg/dL. Rybelsus was increased from 3mg to 7mg, and 7mg was continued after that. In Feb 2022, her HbA1c and 30-min post-prandial glucose was 234 mg/dL, with body weight 82kg. Thus, after increasing the dose of Lybersus, HbA1c decreased from 13.2% to 7.7% and the body weight decreased from 85 kg to 77 kg (Figure 1).
Figure 1: Clinical progress with changes in HbA1c and body weight for oral semaglutide.
Medical problems
According to the obtained
data of history, exams and clinical course, medical problems would be
summarized as follows. They are #1 obesity, #2 T2DM, #3 Gastro Esophageal
Reflux Disease (GERD) and #4 fatty liver. Concerning her medication so far, she
has continued metformin 1000mg and empagliflozin 25mg per day and recently
Rybelsus 3mg, 7mg (#2), and Lansoprazole 15mg per day for years (#3). Oral
semaglutide shows clinical effect on #1 and #4.
Ethical Review
Current study was
performed in compliance with the Declaration of Helsinki, which was revised at
WMA Fortaleza General Assembly in 2013. Furthermore, it was along with the
ethical guidelines for human-based medical research that was notified by
Ministry of Education, Culture, Sports, Science and Technology [MEXT] and also
Ministry of Health, Labour and Welfare [MHLW]. The protocol and examination
were explained to the patient in advance. Concerning this project, a consent
form was obtained from the case. This study was discussed and obtained the
approval of the Ethics Review Committee of Yoshinogawa hospital. The committee
included the director, physician, head nurse, pharmacist, and legal professional.
In recent years, GLP-1Ras
have attracted attention in diabetic practice. Among them, semaglutide was
developed for the first novel oral agent after long years of research
continuation [21]. It became possible for pharmacological invention for the
co-formulation of the peptide associated with the sodium
N-[8-(2-hydroxybenzoyl) amino] caprylate (SNAC) [22]. By the function of SNAC,
the difficult situation concerning the absorption of semaglutide peptide in
strong acidic fluid in the stomach could be overcome. For medical effect of
Rybelsus, cardiovascular safety was observed as non-inferiority compared with
placebo group [23]. Consequently, evolutionary process of oral intake can lead
more beneficial treatment for many patients with T2D.
Semaglutide has been
studied in various kinds of trials. As a novel aspect, it has two route
possible agent including by injection and also per os. The well-known projects
include three categories, which are i) SUSTAIN (Semaglutide Unabated
Sustainability in Treatment of Type 2 Diabetes), ii) STEP (Semaglutide
Treatment Effect in People with Obesity) and iii) Peptide InnOvatioN for Early
diabEtes tReatment (PIONEER). As for these trials, detail contents show i)
once-weekly subcutaneously administration of 1.0 mg, ii) once-weekly
subcutaneously 2.4mg, and iii) oral administration. From various results of
these studies, semaglutide showed the similar efficacy of glucose variability
and satisfactory weight reduction in comparison with other anti-diabetic agents
[24].
Among several
investigations of PIONEER, Japanese T2D patients were studied for their safety
and effect in PIONEER 9 and 10 [25]. The protocol revealed the clinical study
of using 3, 7, and 14mg of oral semaglutide (Rybelsus), subcutaneous dulaglutide
and subcutaneous liraglutide for the period of 52 weeks. The results showed
that 701 cases have shown clinical effect and not remarkable adverse events.
Consequently, semaglutide of injestable and oral routes have showed clinical
effects for patients with all ages.
For current case, we kept
the doses of 7mg, and did not increase 14mg. It was because she has the problem
of GERD. Our medical team do not usually increase Rybelsus dose abruptly. By
explaining the detail characteristic of this agent, the patient was advised to
take medicine along to our schedule. She can always keep certain fasting time
period after taking Rybelsus about 60-90 minutes. As regard to the medication
package insert of Rybelsus, 30-minutes fasting after administration would be the
standard time period [15]. By regulating the fasting time for 30, 60, 120
minutes, the concentration in the blood can show much different. She could keep
fasting time after meds rather long, and she could continue to take Rybelsus
without any Gastrointestinal adverse effects (GIAEs).
The relationship between
blood concentration of semaglutide and fasting time period after taking med was
investigated [26]. The measured data could be obtained from the reported
figures concerning concentration and time period. The semaglutide concentration
would be compared in the case of 15, 30, 60, 120 minutes, respectively. When
the standard concentration is estimated as 1.00 for 15 minutes, the ratio of
semaglutide concentration after 4 hours taking med would be calculated as 1.67
(30 min), 2.60 (60 min) and 3.06 times (120 min), respectively [27]. In
addition, water volume study showed no apparent changes between 50mL and 120mL
that is taken simultaneously with Rybelsus [15]. These results revealed
positive efficacy of semaglutide associated with SNAC for drug delivery system
(DDS) [28]. Several recommended doses were shown from previous phase three
clinical studies [29,30].
This case showed
remarkable reduction of body weight and HbA1c by the administration of oral
semaglutide. Her weight was 77kg in Apr 2020, which was most decreased level so
far. She was planned to be followed up, but her successive clinical management
was transferred to another clinic due to her family situations. Some
limitations may exist in the current case. She has several medical problems of
T2D, obesity, fatty liver and GERD. From gastro-intestinal function, this case
kept 7mg of Rybelsus and did not reveal GIAEs. In summary, 61-year-old female
with T2D received the treatment of oral semaglutide. She showed clinical
improvement as -4.2% of HbA1c and -8kg in weight for 4 months, indicating
satisfactory clinical efficacy. This article would hopefully provide some
reference for diabetic research and practice.
Conflict of interest: The authors declare no conflict of interest.
Funding:
There was no funding received for this paper.
22.
Bittner
B, McIntyre C, Tian H, Tang K, Shah N, Phuapradit W, et al. Phase I clinical
study to select a novel oral formulation for ibandronate containing the
excipient sodium N-[8-(2-hydroxybenzoyl) amino] caprylate (SNAC). Pharmazie.
2012; 67: 233-241.
23.
Andersen
A, Knop FK, Vilsbøll T. A Pharmacological and Clinical Overview of Oral
Semaglutide for the Treatment of Type 2 Diabetes. Drugs. 2021; 81: 1003-1030.
24.
Singh
G, Krauthamer M, Bjalme-Evans M. Wegovy (semaglutide): a new weight loss drug
for chronic weight management. J Investig Med. 2022; 70: 5-13.
25.
Yamada
Y, Yabe D, Hertz CL, Horio H, Nakamura J, Nielsen AM, et al. Efficacy and
safety of oral semaglutide by baseline age in Japanese patients with type 2
diabetes: A subgroup analysis of the PIONEER 9 and 10 Japan trials. Diabetes
Obes Metab. 2022; 24: 321-326.
26.
Bækdal
TA, Breitschaft A, Donsmark M, Maarbjerg SJ, Søndergaard FL, Borregaard J.
Effect of Various Dosing Conditions on the Pharmacokinetics of Oral Semaglutide,
a Human Glucagon-Like Peptide-1 Analogue in a Tablet Formulation. Diabetes
Ther. 2021; 12: 1915-1927.
27.
Miki
K, Bando H, Hayashi K, Dohi A, Kamoto A. Longer Fasting After Rybelsus
Administration Contributes Higher Efficacy. SunText Rev Med Clin Res. 2022; 3:
150.
28.
Buckley
ST, Bækdal TA, Vegge A, Maarbjerg SJ, Pyke C, Ahnfelt-Rønne J, et al.
Transcellular stomach absorption of a derivatized glucagon-like peptide-1
receptor agonist. Sci Transl Med. 2018; 10: 7047.
29.
Rosenstock
J, Allison D, Birkenfeld AL, Blicher TM, Deenadayalan S, Jacobsen JB, et al.
Effect of Additional Oral Semaglutide vs Sitagliptin on Glycated Hemoglobin in
Adults With Type 2 Diabetes Uncontrolled With Metformin Alone or With
Sulfonylurea: The PIONEER 3 Randomized Clinical Trial. JAMA. 2019; 321:
1466-1480.
30.
Rodbard
HW, Rosenstock J, Canani LH, Deerochanawong C, Gumprecht J, Lindberg SØ, et al.
Oral Semaglutide Versus Empagliflozin in Patients With Type 2 Diabetes
Uncontrolled on Metformin: The PIONEER 2 Trial. Diabetes Care. 2019; 42: 2272-2281.